Overview

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Status:
Completed

Trial end date:
2011-09-28

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of patients with newly diagnosed glioblastoma multiforme.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Dacarbazine
Temozolomide